APOA1 and atherosclerosis: Although many researchers have attempted to use direct measurements of MPO in plasma as a biomarker of atherosclerosis [39, 40], we suggest that a marker such as the apoA-I/apoA-II heterodimer, which would reflect MPO activity limited to atherosclerotic lesions, is a better indicator of the atherosclerotic state than plasma MPO activity.